C. Kållberg

The effect of generic market entry on antibiotic prescriptions in the United States

E. Klein, R. Laxminarayan, J. Røttingen, 2021, Nature Communications.

Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions.

R. Laxminarayan, H. Salvesen Blix, C. Kållberg, 2019, ACS infectious diseases.

Introduction and geographic availability of new antibiotics approved between 1999 and 2014

E. Klein, R. Laxminarayan, J. Røttingen, 2018, PloS one.

Identification of the essential features for an effective Demerit Point System. Criteria for BEST Practice Demerit POINT Systems BESTPOINT, Deliverable 2.

Jean-Pascal Assailly, J.-P. Authried, N. Dabrowska-Loranc, 2012 .

The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study

Unni Gopinathan, L. Mathiesen, C. Kållberg, 2023, Journal of Pharmaceutical Policy and Practice.